BMS Consolidates Global Operations

PharmaManufacturing.com
09/23/2005

Bristol-Myers Squibb announced September 20 that it has reorganized its operating units, consolidating its global pharmaceutical operations under the leadership of Lamberto Andreotti, who has been promoted to executive vice president, Bristol-Myers Squibb, and president, Worldwide Pharmaceuticals.

"As our portfolio continues to evolve and we launch additional new medications around the world — with one approval, two recent favorable advisory committee votes, and a potential regulatory submission in 2005 alone — it makes great sense to combine our U.S. and international pharmaceutical operations in one group, to help us maximize opportunities and realize greater efficiencies," said Peter R. Dolan, CEO, Bristol-Myers Squibb.

"Lamberto is an outstanding leader, with an impressive track record at Bristol-Myers Squibb of growing key franchises and businesses around the world, aligning our global R&D and business strategies, attracting and developing top-notch and diverse talent, instilling a culture of compliance, and executing our strategy to build global leadership for the company in areas of significant unmet medical need," Dolan continued. "This realignment will help him expand on these successes, and take them to the next level as our portfolio fully transitions and we prepare to return to expected sales and earnings growth beginning in 2007."

Most recently, Andreotti served as senior vice president and president, International, with responsibility for the company's pharmaceutical operations in Europe, the Middle East and Africa; Japan; and Asia-Pacific. He also was responsible for Mead Johnson Nutritionals, leading provider of infant formula and other nutritional products, and ConvaTec, maker of ostomy and wound therapeutics products.

"There couldn't be a better moment to assume worldwide responsibility for the pharmaceutical business of Bristol-Myers Squibb," said Andreotti. "As we enter a period when major exclusivity losses should be behind us for sometime, I have the exciting task of continuing the positive momentum created by our key growth drivers, and launching several promising new products, assuming approval, that address serious diseases and conditions."

Andreotti will continue to work with Elliott Sigal, the company's chief scientific officer and president, Pharmaceutical Research Institute, who also reports to the CEO.

The company's nonpharmaceutical businesses will be consolidated into a new health care group. The presidents of these three operations — Mead Johnson Nutritionals' Steve Golsby, ConvaTec's Gary Restani and Bristol-Myers Squibb Medical Imaging's Cory Zwerling — will report to the CEO on an interim basis.

"The consolidation of our health care businesses within one group will help us better identify and capitalize on the strategic opportunities of those businesses, while also developing an outstanding global management team," Dolan said. "All three companies — Mead Johnson, ConvaTec and Medical Imaging — have been important contributors to the strength and stability of our company, and have excellent additional growth prospects."